A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This is a triple cohort, open-label pilot study of the safety and antiviral activity of a
single infusion of autologous CD4+ T cells genetically modified at the CCR5 gene by Zinc
Finger Nucleases SB-728mR (ZFN Modified CD4+ T Cells) using electroporated mRNA with or
without the prior administration of two different doses of cyclophosphamide.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)